Clinical Trials · NCT01630590
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 62
- Start date
- Jan 2014
- Locations
- 1 site, United States
- Primary endpoint
- Progression Free Survival